α-interferon therapy induces improvement of platelet counts in children with chronic idiopathic thrombocytopenic purpura

American Journal of Pediatric Hematology/Oncology

Volumn 23, Issue 9, 2001, Pages 598-603

  Donato, Hugo ^a,b   Kohan, Regina ^c   Picón, Armando ^d   Rovó, Alicia ^a   Rapetti, María Cristina ^f   Schvartzman, Gabriel ^b   Lavergne, Marta ^c   de Galvagni, Ana ^f   Rosso, Alicia ^e   Rendo, Pablo ^a  

^a Bio Sidus   (Argentina)

^b Policlínica Bancaria ^*  (Argentina)

^c HOSPITAL GENERAL DE NIÑOS PEDRO DE ELIZALDE   (Argentina)

^d HOSPITAL NACIONAL PROFESOR ALEJANDRO POSADAS   (Argentina)

^e HOSPITAL RAMOS MEJÍA   (Argentina)

^f Hospital de Ninos de San Justo   (Argentina)

Author keywords

Idiopathic thrombocytopenic purpura; Interferon; Purpura; Thrombocytopenia

Indexed keywords

ALPHA INTERFERON; ALPHA2B INTERFERON; IMMUNOGLOBULIN; PREDNISOLONE; RECOMBINANT GAMMA INTERFERON; VINCRISTINE;

ADOLESCENT; ADULT; ARTICLE; CANCER REGRESSION; CHILD; CLINICAL ARTICLE; DRUG EFFICACY; FEMALE; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; MALE; PATIENT MONITORING; PRIORITY JOURNAL; SPLENECTOMY; THROMBOCYTE COUNT; TREATMENT OUTCOME;

ADOLESCENT; ADULT; BIOLOGICAL RESPONSE MODIFIERS; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INTERFERON ALFA-2B; MALE; PLATELET COUNT; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; TREATMENT OUTCOME;

EID: 0035696319     PISSN: 01928562     EISSN: None     Source Type: Journal    
DOI: 10.1097/00043426-200112000-00009     Document Type: Article

References (41)

1. Beardsley DS. Platelet abnormalities in infancy and childhood. In: Nathan DG, Oski FA, eds. Hematology of Infancy and Childhood. Philadelphia: WB Saunders, 1993: 1561-604.
2. Donato H, Picón A, Rapetti MC, et al. Evaluation of prognostic factors in childhood idiopathic thrombocytopenic purpura (abstract 1444). Br J Haematol 1998; 102: 361.
3. Posey DL, Marks C. Overwhelming postsplenectomy sepsis in childhood. Am J Surg 1983; 145: 318-22.
4. Proctor SJ, Jackson G, Carey P, et al. Improvement of platelet counts in steroid-unresponsive idiopathic immune thrombocytopenic purpura after short-course therapy with recombinant α 2b interferon. Blood 1989; 6: 1894-7.
5. Proctor SJ. Alpha interferon therapy in the treatment of idiopathic thrombocytopenic purpura. Eur J Cancer 1991; 27 (S4): S63-8.
6. Iannaccaro P, Molica S, Santoro R, et al. Recombinant alpha-2b interferon in refractory idiopathic immune thrombocytopenia. Eur J Haematol 1992; 48: 271.
7. Dubbeld P, Hillen HFP, Schouten HC. Interferon treatment of refractory idiopathic thrombocytopenic purpura (ITP). Eur J Haematol 1994; 52: 233-5.
8. Cohn RJ, Schwyzer R, Hesseling PB, et al. α-Interferon therapy for severe chronic idiopathic thrombocytopenic purpura in children. Am J Hematol 1993; 43: 246-50.
9. Hayanni A, Mahoney DH, Steuber P, et al. Recombinant interferon alfa-2b therapy in children with immune thrombocytopenic purpura. Pediatr Hematol Oncol 1993; 10: 293-6.
10. Ellis ME, Neal KR, Leen CLS. Alpha-2a recombinant interferon in HIV associated thrombocytopenia. Br Med J 1987; 295: 1519.
11. Lever AML, Brook MG, Yap I, et al. Treatment of thrombocytopenia with alpha interferon. Br Med J 1987; 295: 1519-20.
12. Zandman-Goddard G, Shoenfeld Y. Successful treatment with recombinant alpha 2β interferon for refractory idiopathic thrombocytopenic purpura. Isr J Med Sci 1992; 28: 390-1.
13. Crossley AR, Dickinson AM, Proctor SJ, et al. Effects of interferon-α therapy on immune parameters in immune thrombocytopenic purpura. Autoimmunity 1996; 24: 81-100.
14. Gutterman JU. Cytokine therapeutics: lessons from interferon alpha. Proc Natl Acad Sci USA 1994; 91: 1198-205.
15. Constanzi JJ, Cooper MR, Scarffe JH, et al. Phase II study of recombinant alpha-2 interferon in resistant multiple myeloma. J Clin Oncol 1985; 3: 654-9.
16. Giles FJ, Singer CRJ, Gray AG, et al. Alpha-interferon therapy for essential thrombocytaemia. Lancet 1988;ii: 70-2.
17. Belluci S, Harousseau JL, Bric P, et al. treatment of essential thrombocytaemia by alpha 2a interferon. Lancet 1988;ii: 960-1.
18. Gisslinger H, Ludwig H, Linkesch W, et al. Long-term interferon therapy for thrombocytosis in myeloproliferative diseases. Lancet 1989;i: 634-7.
19. Talpaz M, Kurzock R, Kantarjian H, et al. Recombinant interferon-alpha therapy of Philadelphia chromosome-negative myeloproliferative disorders with thrombocytosis. Am J Med 1989; 86: 554-8.
20. + cells from autoimmune thrombocytopenic purpura (ATP) patients: Their implication in the clinical course of the disease. Am J Hematol 1995; 49: 271-6.
21. Imbach P, Kühne T. Immune thrombocytopenic purpura ITP. Vox Sang 1998; 74 (S2): 309-14.
22. Andersson J. Cytokines in idiopathic thrombocytopenic purpura (ITP). Acta Paediatr 1998; 424 (S): 61-4.
23. McMillan R. The pathogenesis of chronic immune (idiopathic) thrombocytopenic purpura. Semin Hematol 2000; 37: 5-9.
24. Neubauer RH, Goldstein L, Rabin H, et al. Stimulation of in vitro immunoglobulin production by interferon-alpha. J Immunol 1985; 134: 299-304.
25. Fleisher TA, Attallah AM, Tosato G, et al. Interferon-mediated inhibition of human polyclonal immunoglobulin synthesis. J Immunol 1982; 129: 1099-103.
26. Pelton BK, Denman AM. Immunoregulatory effects of interferon-alpha. I. Interferon-alpha inhibits in vitro antibody synthesis by normal human lymphocytes. Clin Exp Immunol 1985; 59: 398-404.
27. Peters M, Ambrus JL, Zheleznyak A, et al. Effect of interferon-alpha on immunoglobulin synthesis by human B cells. J Immunol 1986; 137: 3153-7.
28. Welsh RM. Natural killer cells and interferon. Crit Rev Immunol 1984; 5: 55-93.
29. Parronchi P, De Carli M, Manetti R, et al. IL-4 and IFN (alpha and gamma) exert opposite regulatory effects on the development of cytolytic potential by Th1 or Th2 human T cells clones. J Immunol 1992; 149: 2977-83.
30. Aul C, Gatterman N, Germing U, et al. Adverse effects of Interferon treatment. In: Aul C, Schneider W, eds. Interferons: Biological Activities and Clinical Efficacy, Berlin: Springer, 1997: 250-66.
31. Kurschel E, Metz-Kurschel U, Niederle N, et al. Investigations of the subclinical and clinical nephrotoxicity of interferon α-2 b in patients with myeloproliferative syndromes. Ren Fail 1991; 13: 87-93.
32. Jones GJ, Itri LM. Safety and tolerance of recombinant interferon alfa-2 a (Roferon™-A) in cancer patients. Cancer 1986; 57: 1709-15.
33. Spiegel RJ. Intron™ A (interferon alfa-2 b): clinical overview and future directions. Semin Oncol 1986; 13 (S2): 89-101.
34. Quesada JR, Talpaz M, Rios A, et al. Clinical toxicity of interferons in cancer patients: a review. J Clin Oncol 1986; 4: 234-43.
35. Imholz B, Imbach P, Baumgartner C, et al. Intravenous immunoglobulin (i.v. IgG) for previously treated acute or for chronic idiopathic thrombocytopenic purpura (ITP) in childhood: A prospective multicenter study. Blut 1988; 56: 63-8.
36. Blanchette VS, Luke B, Andrew M, et al. A prospective, randomized trail of high-dose intravenous gammaglobulin G therapy, oral prednisone therapy, and no therapy in childhood acute immune thrombocytopenic purpura. J Pediatr 1993; 123: 989-95.
37. Bussel JB. Splenectomy-sparing strategies for the treatment and long-term maintenance of chronic idiopathic (immune) thrombocytopenic purpura. Semin Hematol 2000; 37 (S1): 1-4.
38. Bennett CL, Weinberg PD, Golub RM, et al. The potential for treatment of idiopathic thrombocytopenic purpura with anti-D to prevent splenectomy: A predictive cost analysis. Semin Hematol 2000; 37 (S1): 26-30.
39. George JN. Treatment options for chronic idiopathic (immune) thrombocytopenic purpura. Semin Hematol 2000; 37 (S1): 31-4.
40. Scaradavou A. Splenectomy-sparing, long-term maintenance with anti-D for chronic immune (idiopathic) thrombocytopenic purpura: The New York Hospital experience. Semin Hematol 2000; 37 (S1): 42-4.
41. Waintarub SE, Brody JI. Use of anti-D in immune thrombocytopenic purpura as a means to prevent splenectomy: Case reports from two university hospital medical centers. Semin Hematol 2000; 37 (S1): 45-4.